High Demand for Breast Implants Drives Stock Up 71% in 2021

  • Establishment Labs shares rise after FDA approval of Motiva implants
  • High demand for breast implants from surgeons and patients
  • Stock up 9.4% to $43.96 on Wednesday
  • 71% increase since the beginning of the year
  • Doubled team of sales representatives to 25 across the U.S.
  • Over 400 plastic surgeons contacted post-announcement

Establishment Labs, a global medical technology company, has seen its shares climb after receiving FDA approval for its Motiva breast implants. The stock price increased by 9.4% to $43.96 on Wednesday following the news. Since the beginning of the year, the share value has surged by 71%. CEO Juan Jose Chacon-Quiros attributes this growth to a surge in demand from both plastic surgeons and patients. In response, Establishment Labs has doubled its team of sales representatives in the U.S., now totaling 25 members. The company has already engaged with over 400 plastic surgeons since announcing the approval.

Factuality Level: 10
Factuality Justification: The article provides accurate information about the company’s stock performance and the demand for its breast implants after FDA approval, along with a quote from the CEO. It does not contain any irrelevant or misleading information, sensationalism, redundancy, personal perspective presented as fact, invalid arguments, logical errors, inconsistencies, fallacies, or false assumptions.
Noise Level: 3
Noise Justification: The article provides relevant information about a company’s stock performance and product demand following FDA approval, but it lacks in-depth analysis or exploration of the broader implications or long-term trends.
Public Companies: Establishment Labs (ESTA)
Key People: Juan Jose Chacon-Quiros (Chief Executive)

Track all markets on TradingView

Financial Relevance: Yes
Financial Markets Impacted: Yes
Financial Rating Justification: The article discusses the increase in shares of Establishment Labs and its breast implant product, which impacts the company’s financial performance and potentially affects related stocks in the medical technology sector.
Presence Of Extreme Event: No
Nature Of Extreme Event: No
Impact Rating Of The Extreme Event: No
Extreme Rating Justification: There is no mention of an extreme event in the text.
Move Size: 9.4%
Sector: Healthcare
Direction: Up
Magnitude: Large
Affected Instruments: Stocks

Reported publicly: www.marketwatch.com